X

Trial Profile

SEN-SURVIVORS: An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary) ; Quercetin (Primary) ; Fisetin
Indications Asthenia
Focus Pharmacodynamics; Therapeutic Use
Acronyms SEN-SURVIVORS

Most Recent Events

01 Aug 2023 Planned End Date changed from 1 Jul 2024 to 1 Dec 2025.
01 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Dec 2024.
06 Jun 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 01 May 2022 to 01 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com